Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibody constant region variant

a constant region and antibody technology, applied in the field of constant region antibodies, can solve the problems of unfavorable binding to the fc receptor, unfavorable method, and posing immunogenicity risks, and achieve the effects of low heterogeneity, high heterogeneity, and reduced antibody heterogeneity

Inactive Publication Date: 2019-07-11
CHUGAI PHARMA CO LTD
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about improving the properties of antibodies used in pharmaceutical agents. By altering the amino acid sequence of the constant regions of antibodies, researchers have created new constant regions with improved properties. These altered constant regions help to produce antibodies with low heterogeneity, which means they are more uniform. The altered constant regions also contribute to the maintenance of the quality of antibody-containing pharmaceuticals. Additionally, by altering specific amino acid residues, researchers have been able to improve the pharmacokinetics of antibodies, meaning they can maintain blood concentration for a longer time with a smaller amount of antibody. This has led to a potential for more effective treatment with the same amount of antibody.

Problems solved by technology

Thus, binding to Fcγ receptor is considered unfavorable in antibody pharmaceuticals intended for neutralizing the biological activity of an antigen from the perspective of side effects and immunogenicity.
A method for impairing the binding to Fcγ receptor is to alter the subtype of the IgG antibody from IgG1 to IgG2 or IgG4; however, this method cannot completely inhibit the binding (Non-patent Document 6).
However, these molecules contain new non-native peptide sequences of nine to twelve amino acids, which may constitute a T-cell epitope peptide and thus pose an immunogenicity risk.
Thus, it was a challenge to secure stability at high concentrations.
However, there has been no report published on the improvement of the stability of IgG at high concentrations by introducing amino acid substitutions into its constant region.
A method for prolonging the antibody half-life in plasma has been reported and it substitutes amino acids in the constant region (Non-patent Documents 14 and 15); however, introduction of non-native sequences into the constant region is unpreferable from the perspective of immunogenicity risk.
It is not easy to manufacture them as a pharmaceutical in a large scale while maintaining differences of objective substance / related substance-related heterogeneity between productions.
However, altered constant regions that meet all of the above requirements have not yet been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody constant region variant
  • Antibody constant region variant
  • Antibody constant region variant

Examples

Experimental program
Comparison scheme
Effect test

example 1

[Example 1] Improvement of C-Terminal Heterogeneities of IgG Molecules

[0366]Construction of an expression vector for H-chain C-terminal ΔGK antibody

[0367]Heterogeneities of the C-terminal sequence of the IgG antibody H chain that have been reported are deletion of the C-terminal amino acid lysine residue, and amidation of the C-terminal carboxyl group due to deletion of both of the two C-terminal amino acids, glycine and lysine residues (Anal Biochem. 2007 Jan. 1; 360(1): 75-83). In TOCILIZUMAB which is an anti-IL-6 receptor antibody, the main component is a sequence in which the C-terminal amino acid lysine present on the nucleotide sequence is deleted by post-translational modification, but an accessory component with remnant lysine and an accessory component with an amidated C-terminal carboxyl group produced by deletion of both glycine and lysine are also present as heterogeneities. It is not easy to manufacture such an antibody as a pharmaceutical in a large scale, while mainta...

example 2

[Example 2] Novel Constant Regions with Reduced Heterogeneity, which Retain the Stability of Natural IgG2

Heterogeneity of Natural IgG1 and Natural IgG2

[0373]For antibody pharmaceuticals against cancer such as those that kill target cells with effector functions and such, IgG1 constant region (isotype) having effector function is preferred. However, for antibody pharmaceuticals that neutralize the functions of a target antigen or antibody pharmaceuticals that bind to target cells but do not kill them, binding to Fcγ receptors is not preferred.

[0374]As methods for decreasing the binding to Fcγ receptors, the method of changing the IgG antibody isotype from IgG1 to IgG2 or IgG4 has been considered (Ann Hematol. 1998 June; 76(6): 231-48), and from the viewpoint of binding to Fcγ receptor I and pharmacokinetics of each isotype, IgG2 was considered to be more desirable than IgG4 (Nat Biotechnol. 2007 December; 25(12): 1369-72). On the other hand, when developing antibodies into pharmaceut...

example 3

[Example 3] Pharmacokinetics-Improving Effect of Novel Constant Region M58-k0 Pharmacokinetics of IgG-Type Antibodies

[0394]The prolonged retention (slow elimination) of IgG molecule in plasma is known to be due to the function of FcRn which is known as a salvage receptor of IgG molecule (Nat. Rev. Immunol. 2007 September; 7(9): 715-25). When taken up into endosomes via pinocytosis, IgG molecules bind to FcRn expressed in endosomes under the acidic conditions within the endosomes (approx. pH 6.0). While IgG molecules that do not bind to FcRn are transferred and degraded in lysosomes, those bound to FcRn are translocated to the cell surface and then released from FcRn back into plasma again under the neutral conditions in the plasma (approx. pH 7.4).

[0395]Known IgG-type antibodies include the IgG1, IgG2, IgG3, and IgG4 isotypes. The plasma half-lives of these isotypes in human are reported to be about 36 days for IgG1 and IgG2; about 29 days for IgG3; and 16 days for IgG4 (Nat. Biotec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional application of U.S. application Ser. No. 14 / 680,250, filed on Apr. 7, 2015, which is a divisional of U.S. application Ser. No. 13 / 257,145, having a 371 (c) date of Nov. 22, 2011, which is the National Stage of International Application Serial No. PCT / JP2010 / 054767, filed on Mar. 19, 2010, which claims priority to Japanese Application Serial Nos. 2009-068631 and 2009-213901, filed on Mar. 19, 2009, and Sep. 16, 2009, respectively.TECHNICAL FIELD[0002]The present invention relates to antibody constant regions with an altered amino acid sequence, and antibodies comprising these constant regions.BACKGROUND[0003]Antibodies are drawing attention as pharmaceuticals as they are highly stable in plasma (blood) and have few side effects. Of these, a number of IgG-type antibody pharmaceuticals are available on the market and many antibody pharmaceuticals are currently under development (Non-patent Documents 1 and 2)....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/00C07K16/28
CPCC07K16/00C07K16/2866C07K16/2875C07K2317/528C07K2317/524C07K2317/52C07K2317/515C07K2317/92C07K2317/53C07K2317/526C07K2317/522C07K2317/76C07K2317/71C07K2317/72C07K2317/94
Inventor IGAWA, TOMOYUKIKURAMOCHI, TAICHIMAEDA, ATSUHIKOSHIRAIWA, HIROTAKE
Owner CHUGAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com